This roundtable series assesses using Bruton kinase inhibitors in patients with chronic lymphocytic leukemia as first-line therapy, as discussed by key opinion leaders and participants at virtual live events.
Fitting Second Generation BTK Inhibitors into the R/R CLL Setting
In the first article of a 2-part series, William G. Wierda, MD, PhD, discusses the role Bruton tyrosine kinase inhibitors play in the relapsed/refractory chronic lymphocytic leukemia setting.
Second Generation BTK Inhibitors Improve Survival in R/R CLL Setting
In the second article of a 2-part series, William G. Wierda, MD, PhD, looks at the efficacy and safety outcomes with the second generation BTK inhibitor zanubrutinib for patients with relapsed/refractory chronic lymphocytic leukemia.
2 Clarke Drive Cranbury, NJ 08512